Jacobson Pharma reported its unaudited results for the six months ended 30 September 2025. Revenue for the period was HKD 766.6 million. Gross profit reached HKD 337.8 million. Profit from operations amounted to HKD 183.4 million. The company recorded a profit before taxation of HKD 173.5 million, while net income amounted to HKD 142.0 million for the half year. Cash and cash equivalents at the end of the period stood at HKD 395.1 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jacobson Pharma Corporation Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251212-11953669), on December 12, 2025, and is solely responsible for the information contained therein.